Jasupa 50 mg, 25 mg FC tablets
PDF Leaflet Revision Date: 14 March 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults who are virologically suppressed.
Dosage (summary)
One tablet once daily with a meal.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pre/periconception period and first trimester; use with caution in second and third trimesters.
Key Drug Interactions
- NNRTIs
- Proton pump inhibitors
- Anticonvulsants
- St. John's wort
Contraindications
- Severe hepatic impairment
- Hypersensitivity to components
- Co-administration with certain drugs
Common side effects
- Diarrhea
- Headache
- Nausea
- Fatigue
- Rash
Counselling Points
- Take with food
- Monitor for hypersensitivity
- Use effective contraception in women of childbearing potential
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Syndrome
- Potential for neural tube defects
Important Disclaimer
The Jasupa 50 mg, 25 mg FC tablets professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
